Tumor treating fields kill cancer cells: Novocure scores FDA nod for Optune in combination with temozolomide for GBM
Fresh off its bid to become a public company, Novocure Ltd. (St. Helier, Jersey Isle) received FDA approval for its Optune device in combination with temozolomide to treat adult patients with newly diagnosed glioblastoma (GBM). Optune is a portable, non-invasive device that delivers low-intensity, intermediate frequency, alternating electric fields referred to as tumor treating fields (TTF) that inhibit cancer cell replication and cause cancer cell death.
Sacked: FDA and CMS taking hits
There are times when we in the private sector think you have to be crazy to want to work at FDA or CMS, but the true unemployment rate is still in excess of 10%. Who in their right mind is going to turn down a steady paycheck in this economy?
A victim of their own success?: Growth of Chinese device industry testing the limits of regulators
Shanghai The speed of growth of the medical device industry in China is stretching regulators to the limit. China is one of the most promising markets for medical devices. In the past few years, a raft of local companies has emerged to compete with the large pool of multinationals that currently have the majority of market share.